Folate transfer across the placenta during late pregnancy in women with epilepsy: A cross‐sectional, two‐center study
Open Access
Abstract
Objective: In women with epilepsy who are treated with antiseizure medications (ASMs), folate concentrations in maternal serum may not be a good indicator of fetal folate supply, because ASMs can interfere with folate handling by the placenta. We aimed to assess the transplacental folate transfer at birth in persons with epilepsy in comparison to controls with no known epilepsy and identify factors affecting it. Methods: This was a cross‐sectional, two‐center study, involving 22 pregnant women with epilepsy treated with ASMs, 10 nontreated pregnant women with epilepsy, and 19 control pregnant individuals with no known epilepsy. Maternal venous blood and umbilical cord blood samples were collected at delivery. Folate concentrations were measured using a validated chemiluminescence assay. ASM concentrations were analyzed in serum and umbilical cord blood. Results: Maternal and neonatal characteristics were generally comparable across the study groups, but cesarian sections were more frequent among controls ( p < .001). Folate concentrations in maternal serum were lower than recommended levels in nine of 26 (35%) of women with epilepsy and eight of 19 (42%) controls. Median cord/maternal serum folate ratios were 1.51 (95% confidence interval [CI] = .92–6.35; n = 17) in women with epilepsy treated with ASMs and 2.02 (95% CI = 1.69–3.71; n = 19) in controls. In women with epilepsy, placental folate transfer was saturable (Cmax = 131.1 ng/mL, 95% CI = 96.4–190.5 ng/mL; Michaelis‐Menten constant, Km = 32.6 ng/mL, 95% CI = 12.5–76.9 ng/mL; adjusted R 2 = .70). Predictability of cord values improved upon exclusion of preterm births (Cmax = 125.2 ng/mL, 95% CI = 97.4–164.7 ng/mL; Km =41.1 ng/mL, 95% CI = 22.4–71.1 ng/mL; adjusted R 2 = .78). Significance: Folate delivery to the fetus during late pregnancy is primarily explained by its concentrations in maternal circulation. In persons with epilepsy, it may be saturable. The frequent apparent folate deficiency observed in our cohort highlights the importance of folate supplementation and monitoring of its levels in maternal circulation throughout pregnancy.Keywords
Funding Information
- Israel Science Foundation (2054/18)
This publication has 46 references indexed in Scilit:
- Neuropsychological Outcomes in 6-Year-Old Children of Women With EpilepsyJAMA Neurology, 2025
- Maternal Serum Folate During Pregnancy and Congenital Heart Disease in OffspringJAMA Network Open, 2024
- Big Data – Big Trouble: The two faces of publishing results from big data studies based on cohorts with poor clinical definitionSeizure: European Journal of Epilepsy, 2023
- Pregnancy, folic acid, and antiseizure medicationClinical Epileptology, 2023
- Association of Folic Acid Supplementation During Pregnancy With the Risk of Autistic Traits in Children Exposed to Antiepileptic Drugs In UteroJAMA Neurology, 2018
- Brief report novel mechanism for valproate‐induced teratogenicityBirth Defects Research Part A: Clinical and Molecular Teratology, 2014
- Antiepileptic drugs interact with folate and vitamin B12 serum levelsAnnals of Neurology, 2011
- WHO Guiding Principles on Human Cell, Tissue and Organ TransplantationCell and Tissue Banking, 2010
- Investigation of megaloblastic anaemia—cobalamin, folate, and metabolite status2006
- Placental Folate Transport and Binding are not Impaired in Pregnancies Complicated by Fetal Growth RestrictionPlacenta, 2004